Seer, Inc. (SEER)
NASDAQ: SEER · Real-Time Price · USD
1.790
-0.060 (-3.24%)
At close: Jun 5, 2026, 4:00 PM EDT
1.785
-0.005 (-0.28%)
After-hours: Jun 5, 2026, 4:04 PM EDT
Seer, Inc. Revenue
Seer, Inc. had revenue of $2.79M in the quarter ending March 31, 2026, a decrease of -33.58%. This brings the company's revenue in the last twelve months to $15.17M, down -0.93% year-over-year. In the year 2025, Seer, Inc. had annual revenue of $16.58M with 16.99% growth.
Revenue (ttm)
$15.17M
Revenue Growth
-0.93%
P/S Ratio
5.94
Revenue / Employee
$133,694
Employees
124
Market Cap
98.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.58M | 2.41M | 16.99% |
| Dec 31, 2024 | 14.17M | -2.49M | -14.95% |
| Dec 31, 2023 | 16.66M | 1.17M | 7.54% |
| Dec 31, 2022 | 15.49M | 8.88M | 134.14% |
| Dec 31, 2021 | 6.62M | 5.96M | 908.69% |
| Dec 31, 2020 | 656.00K | 540.00K | 465.52% |
| Dec 31, 2019 | 116.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Verrica Pharmaceuticals | 37.16M |
| Pyxis Oncology | 13.86M |
| Coya Therapeutics | 7.94M |
| Cibus | 3.64M |
| Cardiff Oncology | 525.00K |
| Inovio Pharmaceuticals | 65.34K |
SEER News
- 2 days ago - Seer Files Definitive Proxy Materials and Mails Letter to Stockholders - GlobeNewsWire
- 2 days ago - Seer, Inc. Proxy statement: Proxy filing - Filings
- 2 days ago - Seer, Inc. Proxy statement: Proxy filing - Filings
- 2 days ago - Seer, Inc. Proxy statement: Proxy filing - Filings
- 4 days ago - Seer, Inc. Proxy statement: Proxy filing - Filings
- 7 days ago - Seer files ITC complaint against Nanomics Biotechnology - TheFly
- 7 days ago - Seer Files ITC Complaint Against Nanomics - GlobeNewsWire
- 9 days ago - The Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All Stockholders - Business Wire